Ruth M. Mitchell

ORCID: 0000-0001-6824-8043
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Historical and Cultural Archaeology Studies
  • Archaeology and ancient environmental studies
  • Pneumonia and Respiratory Infections
  • Respiratory viral infections research
  • Bacterial Infections and Vaccines
  • T-cell and B-cell Immunology
  • Cystic Fibrosis Research Advances
  • American Environmental and Regional History
  • Pacific and Southeast Asian Studies
  • Global Maritime and Colonial Histories
  • Biblical Studies and Interpretation
  • Pentecostalism and Christianity Studies
  • Oral History, Memory, Narrative Analysis
  • Turfgrass Adaptation and Management
  • Archaeological Research and Protection
  • Archaeology and Natural History
  • Architecture, Design, and Social History
  • Neonatal Respiratory Health Research
  • Pelvic and Acetabular Injuries
  • Colonialism, slavery, and trade
  • Complement system in diseases
  • Immunodeficiency and Autoimmune Disorders
  • Hip and Femur Fractures
  • Influenza Virus Research Studies
  • Immunotherapy and Immune Responses

Wythenshawe Hospital
2021

Manchester University NHS Foundation Trust
2018-2021

University of Oxford
2013-2017

Oxford BioMedica (United Kingdom)
2014-2017

Oxford Biomedical Research
2014

Science Oxford
2014

Weatherford College
2013

Oxfam
2013

Churchill Hospital
2013

City University of Seattle
2011

Patients with osteoporotic vertebral fractures are at increased risk of hip fracture. In a cohort fracture patients, many had previous imaging studies showing incidental fractures. Fifty-four percent were not reported by the radiologist, highlighting missed opportunity for diagnosing and treating osteoporosis, thereby preventing further fragility (VFFs) future fractures, including Treating osteoporosis in these patients has potential to reduce subsequent which associated high morbidity,...

10.1007/s11657-017-0363-y article EN cc-by Archives of Osteoporosis 2017-08-07

The introduction of vaccines containing the capsular polysaccharides N. meningitidis, S. pneumonia, and H. influenzae type b has driven a significant reduction in cases disease caused by these bacteria. polysaccharide-specific antibody responses following vaccination are well characterized, however less is known about B cells underlying this response. Here, we summarize plasma cell (PC) memory (BMEM) plain polysaccharide protein-polysaccharide conjugate vaccination, drawing together studies...

10.4161/hv.28350 article EN Human Vaccines & Immunotherapeutics 2014-03-14

Introduction Ivacaftor was the first therapy licensed to address underlying defect in cystic fibrosis (CF). The improvements lung function, nutritional status and pulmonary exacerbations patients carrying a Gly551Asp mutation were greater than previously seen clinical trials for other therapies. Limited data are available regarding long-term outcomes adherence ivacaftor outside trials. Methods We conducted 5-year single-centre retrospective study of people with CF Gly 551 Asp who received...

10.1136/thoraxjnl-2020-215556 article EN Thorax 2021-02-12

The ELISpot assay is used in vaccine studies for the quantification of antigen-specific memory B cells (BMEM), and can be performed using cryopreserved samples. effects cryopreservation on BMEM detection consistency cultured assays when by different operators or laboratories are unknown. In this study, blood was taken from healthy volunteers, a to count specific 2 routine antigens (diphtheria tetanus toxoid). Results were assessed intra- inter-operator variation, cryopreservation....

10.4161/hv.29318 article EN Human Vaccines & Immunotherapeutics 2014-06-18

Background: Vaccine-induced immunity against pneumococcal infection relies on the generation of high concentrations antibody and B cell memory. Both 10- 13-valent conjugate vaccines (PCV-10 PCV-13) effectively reduce disease caused by vaccine serotypes. It is unknown whether memory requires several doses same or different PCVs are interchangeable. Methods: Children in United Kingdom (n=178) who had previously received PCV-13 at 2 4 months were randomized 1:1 to receive a PCV-10 booster age...

10.1097/inf.0000000000001497 article EN The Pediatric Infectious Disease Journal 2016-12-25
Coming Soon ...